 Csaba Galambos
Concepts (485)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Alveoli | 17 | 2023 | 383 | 2.770 |
Why?
| | Persistent Fetal Circulation Syndrome | 10 | 2023 | 138 | 2.600 |
Why?
| | Lung | 34 | 2026 | 4109 | 2.540 |
Why?
| | Respiratory Insufficiency | 6 | 2023 | 326 | 2.230 |
Why?
| | Pulmonary Artery | 12 | 2026 | 1134 | 2.220 |
Why?
| | Pulmonary Veins | 5 | 2019 | 105 | 1.670 |
Why?
| | Arteriovenous Anastomosis | 4 | 2022 | 13 | 1.570 |
Why?
| | Bronchial Arteries | 3 | 2018 | 12 | 1.570 |
Why?
| | Hypertension, Pulmonary | 19 | 2026 | 1980 | 1.540 |
Why?
| | T-Box Domain Proteins | 5 | 2026 | 106 | 1.390 |
Why?
| | Bronchi | 6 | 2023 | 267 | 1.380 |
Why?
| | Pulmonary Circulation | 7 | 2022 | 430 | 1.160 |
Why?
| | Glycogen Storage Disease | 4 | 2021 | 19 | 1.100 |
Why?
| | Down Syndrome | 6 | 2021 | 534 | 1.020 |
Why?
| | Infant, Newborn | 37 | 2024 | 6429 | 0.990 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2023 | 197 | 0.970 |
Why?
| | Immunohistochemistry | 13 | 2017 | 1716 | 0.960 |
Why?
| | Lung Diseases | 9 | 2024 | 787 | 0.930 |
Why?
| | Homeodomain Proteins | 4 | 2017 | 523 | 0.920 |
Why?
| | Infant | 38 | 2025 | 10034 | 0.900 |
Why?
| | Abnormalities, Multiple | 3 | 2016 | 197 | 0.860 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2024 | 410 | 0.850 |
Why?
| | Lung Diseases, Interstitial | 6 | 2021 | 660 | 0.850 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2014 | 49 | 0.790 |
Why?
| | Lymphatic Vessels | 3 | 2009 | 63 | 0.770 |
Why?
| | Heart Defects, Congenital | 6 | 2022 | 914 | 0.750 |
Why?
| | Germ-Line Mutation | 1 | 2023 | 172 | 0.750 |
Why?
| | Cardiovascular Abnormalities | 1 | 2022 | 15 | 0.740 |
Why?
| | Sudden Infant Death | 1 | 2022 | 39 | 0.720 |
Why?
| | Imaging, Three-Dimensional | 5 | 2026 | 583 | 0.680 |
Why?
| | Capillaries | 3 | 2014 | 124 | 0.670 |
Why?
| | Humans | 94 | 2026 | 144759 | 0.640 |
Why?
| | Graft Rejection | 5 | 2013 | 540 | 0.610 |
Why?
| | Mutation | 13 | 2025 | 4089 | 0.610 |
Why?
| | Tumor Suppressor Proteins | 3 | 2011 | 321 | 0.600 |
Why?
| | Histological Techniques | 2 | 2009 | 38 | 0.590 |
Why?
| | Death, Sudden | 1 | 2019 | 24 | 0.590 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2009 | 157 | 0.580 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 97 | 0.570 |
Why?
| | Fatal Outcome | 7 | 2019 | 307 | 0.560 |
Why?
| | Child, Preschool | 25 | 2021 | 11787 | 0.550 |
Why?
| | Gene Deletion | 1 | 2019 | 389 | 0.540 |
Why?
| | Pneumonia | 2 | 2022 | 631 | 0.530 |
Why?
| | Pneumonia, Lipid | 1 | 2017 | 3 | 0.530 |
Why?
| | Child | 36 | 2023 | 22633 | 0.510 |
Why?
| | Airway Obstruction | 1 | 2019 | 162 | 0.510 |
Why?
| | Virus Diseases | 2 | 2009 | 216 | 0.500 |
Why?
| | Collagen Type VIII | 1 | 2016 | 3 | 0.500 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2016 | 9 | 0.490 |
Why?
| | Collagen Type IV | 1 | 2016 | 28 | 0.490 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2016 | 64 | 0.480 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2015 | 10 | 0.470 |
Why?
| | Hernias, Diaphragmatic, Congenital | 3 | 2024 | 219 | 0.460 |
Why?
| | Veins | 1 | 2016 | 68 | 0.460 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 210 | 0.440 |
Why?
| | X-Ray Microtomography | 3 | 2026 | 107 | 0.440 |
Why?
| | Male | 51 | 2025 | 72315 | 0.440 |
Why?
| | Microvessels | 1 | 2016 | 99 | 0.430 |
Why?
| | Anemia, Sickle Cell | 1 | 2019 | 312 | 0.430 |
Why?
| | Sarcoma | 1 | 2017 | 205 | 0.420 |
Why?
| | Arteriovenous Fistula | 1 | 2014 | 38 | 0.420 |
Why?
| | Transcription Factors | 3 | 2023 | 1741 | 0.400 |
Why?
| | Autoantigens | 1 | 2016 | 429 | 0.390 |
Why?
| | Hypoxia | 2 | 2019 | 1199 | 0.390 |
Why?
| | Female | 45 | 2026 | 78271 | 0.390 |
Why?
| | Lymphangiogenesis | 2 | 2011 | 27 | 0.380 |
Why?
| | Nuclear Proteins | 2 | 2010 | 748 | 0.380 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 2 | 2009 | 7 | 0.380 |
Why?
| | Endothelium, Lymphatic | 3 | 2009 | 11 | 0.370 |
Why?
| | Complement C4b | 2 | 2013 | 9 | 0.360 |
Why?
| | ABO Blood-Group System | 2 | 2011 | 57 | 0.360 |
Why?
| | Tomography, X-Ray Computed | 8 | 2022 | 2730 | 0.360 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1519 | 0.350 |
Why?
| | Sensitivity and Specificity | 6 | 2017 | 1985 | 0.340 |
Why?
| | Heart Neoplasms | 2 | 2022 | 55 | 0.340 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1313 | 0.340 |
Why?
| | Diagnosis, Differential | 8 | 2017 | 1489 | 0.340 |
Why?
| | Biomarkers | 8 | 2024 | 4271 | 0.330 |
Why?
| | Erythema | 1 | 2010 | 28 | 0.320 |
Why?
| | Asthma | 2 | 2021 | 1767 | 0.320 |
Why?
| | Vena Cava, Superior | 1 | 2010 | 25 | 0.320 |
Why?
| | Teratoma | 2 | 2025 | 120 | 0.320 |
Why?
| | Phosphoproteins | 2 | 2018 | 344 | 0.320 |
Why?
| | Forkhead Transcription Factors | 3 | 2023 | 202 | 0.320 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2010 | 36 | 0.320 |
Why?
| | Scalp | 2 | 2010 | 37 | 0.310 |
Why?
| | Vena Cava, Inferior | 1 | 2010 | 81 | 0.300 |
Why?
| | Ranula | 1 | 2009 | 3 | 0.300 |
Why?
| | Mucocele | 1 | 2009 | 12 | 0.300 |
Why?
| | Phenotype | 6 | 2025 | 3162 | 0.290 |
Why?
| | Pathology | 1 | 2009 | 21 | 0.290 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.290 |
Why?
| | Pleural Effusion | 2 | 2021 | 60 | 0.290 |
Why?
| | Vascular Malformations | 1 | 2009 | 50 | 0.280 |
Why?
| | Hemodynamics | 5 | 2021 | 1121 | 0.280 |
Why?
| | Adolescent | 18 | 2025 | 22428 | 0.280 |
Why?
| | Pulmonary Surfactant-Associated Protein C | 2 | 2021 | 45 | 0.280 |
Why?
| | Peptide Fragments | 2 | 2013 | 699 | 0.270 |
Why?
| | Cryopreservation | 1 | 2009 | 110 | 0.270 |
Why?
| | Endocardium | 1 | 2007 | 31 | 0.260 |
Why?
| | Disease Models, Animal | 8 | 2026 | 4557 | 0.260 |
Why?
| | Heart Transplantation | 3 | 2013 | 736 | 0.250 |
Why?
| | Viruses | 1 | 2009 | 165 | 0.250 |
Why?
| | Heart Ventricles | 4 | 2022 | 760 | 0.240 |
Why?
| | Infant, Premature | 3 | 2023 | 611 | 0.240 |
Why?
| | Hemorrhage | 2 | 2021 | 809 | 0.240 |
Why?
| | Biopsy | 9 | 2024 | 1075 | 0.240 |
Why?
| | Temporal Muscle | 1 | 2005 | 3 | 0.230 |
Why?
| | Vascular Resistance | 2 | 2019 | 367 | 0.230 |
Why?
| | Staining and Labeling | 1 | 2026 | 151 | 0.230 |
Why?
| | Choristoma | 1 | 2005 | 21 | 0.230 |
Why?
| | Herpesvirus 8, Human | 1 | 2006 | 68 | 0.230 |
Why?
| | Thyroid Nuclear Factor 1 | 2 | 2019 | 16 | 0.230 |
Why?
| | Neovascularization, Physiologic | 1 | 2007 | 194 | 0.230 |
Why?
| | Submandibular Gland | 1 | 2025 | 20 | 0.220 |
Why?
| | Nose Neoplasms | 1 | 2025 | 21 | 0.220 |
Why?
| | Interleukin-5 | 1 | 2025 | 39 | 0.220 |
Why?
| | Carcinosarcoma | 1 | 2025 | 23 | 0.220 |
Why?
| | Churg-Strauss Syndrome | 1 | 2025 | 27 | 0.220 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 381 | 0.220 |
Why?
| | Young Adult | 7 | 2023 | 14105 | 0.220 |
Why?
| | Vascular Remodeling | 3 | 2026 | 205 | 0.220 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2024 | 24 | 0.210 |
Why?
| | Microscopy, Phase-Contrast | 2 | 2021 | 18 | 0.210 |
Why?
| | Synchrotrons | 2 | 2021 | 13 | 0.210 |
Why?
| | Soft Tissue Neoplasms | 1 | 2005 | 127 | 0.200 |
Why?
| | Mice, Knockout | 3 | 2026 | 3121 | 0.200 |
Why?
| | Hemangiopericytoma | 1 | 2003 | 5 | 0.190 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 183 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 985 | 0.190 |
Why?
| | Infant Death | 1 | 2022 | 9 | 0.190 |
Why?
| | Aorta | 2 | 2019 | 429 | 0.190 |
Why?
| | Arteriovenous Malformations | 1 | 2022 | 29 | 0.190 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 64 | 0.180 |
Why?
| | Fibroma | 1 | 2022 | 20 | 0.180 |
Why?
| | Lung Transplantation | 2 | 2019 | 338 | 0.180 |
Why?
| | Severity of Illness Index | 5 | 2018 | 2925 | 0.180 |
Why?
| | Lymphokines | 1 | 2002 | 130 | 0.180 |
Why?
| | Serotonin | 1 | 2024 | 293 | 0.180 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2022 | 52 | 0.180 |
Why?
| | Fibrin | 1 | 2023 | 91 | 0.180 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 40 | 0.180 |
Why?
| | Myocardium | 2 | 2017 | 939 | 0.180 |
Why?
| | Antibodies, Viral | 1 | 2006 | 672 | 0.170 |
Why?
| | Cell Proliferation | 4 | 2019 | 2496 | 0.170 |
Why?
| | Sjogren's Syndrome | 1 | 2021 | 37 | 0.170 |
Why?
| | Protein C | 1 | 2021 | 53 | 0.170 |
Why?
| | Hemangiosarcoma | 1 | 2021 | 23 | 0.170 |
Why?
| | Epilepsy | 1 | 2005 | 376 | 0.170 |
Why?
| | Vasculitis | 1 | 2021 | 69 | 0.160 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 100 | 0.150 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 7 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2021 | 168 | 0.150 |
Why?
| | Athetosis | 1 | 2019 | 7 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 237 | 0.150 |
Why?
| | Congenital Hypothyroidism | 1 | 2019 | 10 | 0.150 |
Why?
| | Chorea | 1 | 2019 | 13 | 0.150 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 24 | 0.150 |
Why?
| | Mitochondrial Diseases | 1 | 2020 | 93 | 0.150 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 19 | 0.140 |
Why?
| | Pulmonary Eosinophilia | 1 | 2018 | 26 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2024 | 3604 | 0.140 |
Why?
| | Heterozygote | 1 | 2019 | 315 | 0.140 |
Why?
| | Exodeoxyribonucleases | 1 | 2018 | 28 | 0.140 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2018 | 9 | 0.140 |
Why?
| | Adult | 9 | 2023 | 40449 | 0.140 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2018 | 31 | 0.140 |
Why?
| | Stenosis, Pulmonary Artery | 1 | 2018 | 4 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2021 | 251 | 0.140 |
Why?
| | Silicosis | 1 | 2018 | 30 | 0.140 |
Why?
| | Gene Expression | 1 | 2023 | 1490 | 0.140 |
Why?
| | Nervous System Malformations | 1 | 2018 | 47 | 0.140 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 270 | 0.140 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2019 | 106 | 0.140 |
Why?
| | Macrophages, Alveolar | 2 | 2012 | 368 | 0.130 |
Why?
| | Histiocytosis | 1 | 2017 | 9 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2021 | 17066 | 0.130 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2018 | 93 | 0.130 |
Why?
| | Contracture | 1 | 2017 | 23 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2018 | 61 | 0.130 |
Why?
| | Pleurisy | 1 | 2017 | 6 | 0.130 |
Why?
| | Macrophage Activation Syndrome | 1 | 2017 | 22 | 0.130 |
Why?
| | Uremia | 1 | 2017 | 15 | 0.130 |
Why?
| | Up-Regulation | 2 | 2020 | 851 | 0.130 |
Why?
| | Animals | 15 | 2026 | 38058 | 0.130 |
Why?
| | Coccyx | 1 | 2017 | 4 | 0.130 |
Why?
| | Heart Failure | 3 | 2021 | 2323 | 0.130 |
Why?
| | Choroid Neoplasms | 1 | 2017 | 9 | 0.130 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2017 | 73 | 0.130 |
Why?
| | Developmental Disabilities | 1 | 2020 | 281 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2017 | 56 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2023 | 1166 | 0.120 |
Why?
| | Collagen Type XVIII | 1 | 2016 | 5 | 0.120 |
Why?
| | Myocardial Contraction | 1 | 2018 | 298 | 0.120 |
Why?
| | Syndrome | 2 | 2010 | 380 | 0.120 |
Why?
| | Sacrum | 1 | 2017 | 78 | 0.120 |
Why?
| | Cadaver | 2 | 2015 | 304 | 0.120 |
Why?
| | Autopsy | 1 | 2016 | 94 | 0.120 |
Why?
| | Kidney | 2 | 2022 | 1495 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 467 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2020 | 737 | 0.120 |
Why?
| | Cell Transdifferentiation | 1 | 2015 | 31 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 675 | 0.110 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2015 | 57 | 0.110 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 111 | 0.110 |
Why?
| | Multiple Myeloma | 1 | 2019 | 291 | 0.110 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 297 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2018 | 250 | 0.110 |
Why?
| | Pancreatic Ducts | 1 | 2015 | 81 | 0.110 |
Why?
| | Muscle Proteins | 1 | 2016 | 244 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2003 | 919 | 0.110 |
Why?
| | Alanine Transaminase | 2 | 2013 | 151 | 0.110 |
Why?
| | Adventitia | 1 | 2014 | 43 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 758 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2017 | 253 | 0.100 |
Why?
| | Genetic Variation | 1 | 2019 | 983 | 0.100 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2013 | 12 | 0.100 |
Why?
| | Algorithms | 1 | 2022 | 1837 | 0.100 |
Why?
| | Radiation Injuries, Experimental | 1 | 2013 | 20 | 0.100 |
Why?
| | Macaca fascicularis | 1 | 2013 | 71 | 0.100 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 74 | 0.100 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2016 | 359 | 0.100 |
Why?
| | Pregnancy | 4 | 2019 | 7190 | 0.100 |
Why?
| | Adenofibroma | 1 | 2013 | 1 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 459 | 0.100 |
Why?
| | Brain | 1 | 2005 | 2933 | 0.100 |
Why?
| | Infant, Extremely Premature | 1 | 2013 | 67 | 0.100 |
Why?
| | Mice | 7 | 2026 | 18339 | 0.090 |
Why?
| | Hyperoxia | 1 | 2014 | 99 | 0.090 |
Why?
| | Hepatocytes | 1 | 2013 | 223 | 0.090 |
Why?
| | Mucin-5B | 1 | 2015 | 234 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2016 | 1782 | 0.090 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 636 | 0.090 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 148 | 0.090 |
Why?
| | Osteopetrosis | 1 | 2012 | 2 | 0.090 |
Why?
| | Mandibular Neoplasms | 1 | 2012 | 22 | 0.090 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2012 | 15 | 0.090 |
Why?
| | Nephrectomy | 1 | 2013 | 158 | 0.090 |
Why?
| | Parasympathetic Nervous System | 1 | 2011 | 26 | 0.090 |
Why?
| | Burkitt Lymphoma | 1 | 2012 | 62 | 0.090 |
Why?
| | Glycogen Storage Disease Type III | 1 | 2011 | 1 | 0.090 |
Why?
| | Blood Group Incompatibility | 1 | 2011 | 20 | 0.090 |
Why?
| | Transplantation, Homologous | 2 | 2011 | 415 | 0.090 |
Why?
| | Transplants | 1 | 2011 | 39 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 905 | 0.080 |
Why?
| | Tissue Culture Techniques | 1 | 2011 | 83 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2025 | 557 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1953 | 0.080 |
Why?
| | Insulin-Secreting Cells | 1 | 2015 | 388 | 0.080 |
Why?
| | Lung Injury | 1 | 2014 | 237 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1982 | 0.080 |
Why?
| | Mannose-Binding Lectins | 1 | 2010 | 10 | 0.080 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 178 | 0.080 |
Why?
| | Prognosis | 4 | 2021 | 4282 | 0.080 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2010 | 17 | 0.080 |
Why?
| | Lectins, C-Type | 1 | 2010 | 62 | 0.080 |
Why?
| | Antigens, CD1 | 1 | 2010 | 60 | 0.080 |
Why?
| | Synovitis, Pigmented Villonodular | 1 | 2010 | 3 | 0.080 |
Why?
| | MicroRNAs | 1 | 2016 | 701 | 0.080 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2010 | 29 | 0.080 |
Why?
| | NF-kappa B | 1 | 2014 | 661 | 0.080 |
Why?
| | Multiple Organ Failure | 2 | 2012 | 124 | 0.080 |
Why?
| | Thyroid Diseases | 1 | 2010 | 43 | 0.080 |
Why?
| | Reference Values | 1 | 2011 | 797 | 0.080 |
Why?
| | Vascular Stiffness | 1 | 2014 | 486 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2025 | 902 | 0.070 |
Why?
| | Islets of Langerhans | 1 | 2015 | 833 | 0.070 |
Why?
| | Tissue Preservation | 1 | 2009 | 12 | 0.070 |
Why?
| | Antigens, CD34 | 1 | 2009 | 88 | 0.070 |
Why?
| | Upper Extremity | 1 | 2010 | 112 | 0.070 |
Why?
| | Arthritis, Infectious | 1 | 2010 | 72 | 0.070 |
Why?
| | Ki-67 Antigen | 1 | 2009 | 117 | 0.070 |
Why?
| | Sampling Studies | 1 | 2009 | 99 | 0.070 |
Why?
| | Face | 1 | 2010 | 173 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1499 | 0.070 |
Why?
| | Disease Management | 1 | 2013 | 645 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2011 | 379 | 0.070 |
Why?
| | Histocompatibility Testing | 1 | 2009 | 121 | 0.070 |
Why?
| | Brain Diseases | 1 | 2010 | 152 | 0.070 |
Why?
| | Time Factors | 4 | 2019 | 7173 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 412 | 0.070 |
Why?
| | Hip Joint | 1 | 2010 | 172 | 0.070 |
Why?
| | Papillomaviridae | 1 | 2009 | 115 | 0.070 |
Why?
| | Acute Disease | 1 | 2011 | 1030 | 0.070 |
Why?
| | Blood-Air Barrier | 1 | 2008 | 12 | 0.070 |
Why?
| | Adenoviridae | 1 | 2009 | 199 | 0.070 |
Why?
| | Cytomegalovirus | 1 | 2009 | 168 | 0.070 |
Why?
| | Glucocorticoids | 2 | 2025 | 535 | 0.070 |
Why?
| | Paraffin Embedding | 1 | 2007 | 32 | 0.070 |
Why?
| | Hormones | 1 | 2008 | 134 | 0.060 |
Why?
| | Antigens, CD | 1 | 2010 | 555 | 0.060 |
Why?
| | Pulmonary Valve | 1 | 2009 | 101 | 0.060 |
Why?
| | Wound Healing | 1 | 2009 | 351 | 0.060 |
Why?
| | Graft Survival | 1 | 2009 | 526 | 0.060 |
Why?
| | Fetal Death | 1 | 2006 | 58 | 0.060 |
Why?
| | Lower Extremity | 1 | 2010 | 438 | 0.060 |
Why?
| | Middle Aged | 5 | 2016 | 35875 | 0.060 |
Why?
| | Signal Transduction | 4 | 2025 | 5226 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3409 | 0.060 |
Why?
| | Apoptosis | 1 | 2014 | 2430 | 0.060 |
Why?
| | Sequence Deletion | 2 | 2022 | 193 | 0.060 |
Why?
| | Liver | 1 | 2013 | 1887 | 0.050 |
Why?
| | Rhabdomyosarcoma | 1 | 2005 | 64 | 0.050 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2025 | 150 | 0.050 |
Why?
| | Fetal Development | 1 | 2008 | 299 | 0.050 |
Why?
| | Fibrosis | 2 | 2017 | 548 | 0.050 |
Why?
| | Insulin | 1 | 2015 | 2507 | 0.050 |
Why?
| | Specimen Handling | 1 | 2006 | 186 | 0.050 |
Why?
| | Neuroglia | 1 | 2005 | 172 | 0.050 |
Why?
| | Sheep | 2 | 2019 | 880 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2025 | 11679 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2004 | 162 | 0.050 |
Why?
| | Comorbidity | 2 | 2020 | 1658 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2004 | 235 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2004 | 204 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2115 | 0.050 |
Why?
| | Endothelial Cells | 2 | 2020 | 869 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 252 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 80 | 0.050 |
Why?
| | Creatinine | 1 | 2024 | 506 | 0.050 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2022 | 15 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2022 | 88 | 0.050 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2002 | 10 | 0.040 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.040 |
Why?
| | Models, Anatomic | 1 | 2002 | 84 | 0.040 |
Why?
| | Myeloproliferative Disorders | 1 | 2002 | 19 | 0.040 |
Why?
| | Meningeal Neoplasms | 1 | 2003 | 94 | 0.040 |
Why?
| | Immunophenotyping | 2 | 2019 | 322 | 0.040 |
Why?
| | Lymphoproliferative Disorders | 1 | 2002 | 57 | 0.040 |
Why?
| | Plasma Cells | 1 | 2002 | 75 | 0.040 |
Why?
| | Heparin | 1 | 2002 | 244 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2002 | 402 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 80 | 0.040 |
Why?
| | Surface-Active Agents | 1 | 2021 | 92 | 0.040 |
Why?
| | Granuloma | 1 | 2021 | 96 | 0.040 |
Why?
| | Bevacizumab | 1 | 2021 | 167 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 2022 | 221 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2002 | 247 | 0.040 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2020 | 42 | 0.040 |
Why?
| | Age of Onset | 1 | 2021 | 551 | 0.040 |
Why?
| | Tumor Hypoxia | 1 | 2019 | 7 | 0.040 |
Why?
| | Risk Factors | 3 | 2020 | 10779 | 0.040 |
Why?
| | Coronary Occlusion | 1 | 2019 | 20 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 54 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 965 | 0.040 |
Why?
| | Risk Assessment | 1 | 2009 | 3671 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 97 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 199 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 689 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 3333 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 195 | 0.030 |
Why?
| | Eosinophils | 1 | 2021 | 316 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2019 | 136 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2026 | 2050 | 0.030 |
Why?
| | Sus scrofa | 1 | 2018 | 64 | 0.030 |
Why?
| | Nucleoside Transport Proteins | 1 | 2017 | 8 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1266 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2019 | 437 | 0.030 |
Why?
| | Tumor Burden | 1 | 2019 | 319 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 115 | 0.030 |
Why?
| | Azathioprine | 1 | 2017 | 49 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 403 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 386 | 0.030 |
Why?
| | Pleura | 1 | 2017 | 28 | 0.030 |
Why?
| | Risk | 1 | 2020 | 911 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2018 | 127 | 0.030 |
Why?
| | Pyrimidines | 1 | 2021 | 532 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 19 | 0.030 |
Why?
| | Sulfonamides | 1 | 2021 | 580 | 0.030 |
Why?
| | Thoracoscopy | 1 | 2017 | 62 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.030 |
Why?
| | Galectin 3 | 1 | 2016 | 21 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 341 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 331 | 0.030 |
Why?
| | Prednisone | 1 | 2017 | 221 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2018 | 547 | 0.030 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 120 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2006 | 5408 | 0.030 |
Why?
| | Methotrexate | 1 | 2017 | 240 | 0.030 |
Why?
| | Neurons | 1 | 2005 | 1640 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 289 | 0.030 |
Why?
| | Radiography | 1 | 2018 | 844 | 0.030 |
Why?
| | Heart | 1 | 2020 | 636 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 357 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 106 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 299 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2020 | 556 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 478 | 0.030 |
Why?
| | Disease Progression | 2 | 2019 | 2847 | 0.030 |
Why?
| | Rare Diseases | 1 | 2015 | 113 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 975 | 0.030 |
Why?
| | Luminescent Proteins | 1 | 2015 | 185 | 0.030 |
Why?
| | North America | 1 | 2015 | 310 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2875 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 732 | 0.030 |
Why?
| | Fetus | 1 | 2019 | 803 | 0.030 |
Why?
| | Elastin | 1 | 2014 | 79 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2019 | 897 | 0.030 |
Why?
| | United States | 3 | 2018 | 15966 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2015 | 201 | 0.030 |
Why?
| | Mice, Inbred ICR | 1 | 2014 | 113 | 0.030 |
Why?
| | Retreatment | 1 | 2013 | 77 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1618 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2014 | 232 | 0.030 |
Why?
| | Regeneration | 1 | 2015 | 197 | 0.030 |
Why?
| | Stents | 1 | 2018 | 556 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 27 | 0.020 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 103 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 118 | 0.020 |
Why?
| | Cohort Studies | 2 | 2018 | 5960 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 145 | 0.020 |
Why?
| | Liver Failure, Acute | 1 | 2013 | 67 | 0.020 |
Why?
| | Autoimmunity | 1 | 2019 | 926 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1813 | 0.020 |
Why?
| | Interleukin-1 | 1 | 2016 | 961 | 0.020 |
Why?
| | Pancreatectomy | 1 | 2015 | 285 | 0.020 |
Why?
| | Gene Dosage | 1 | 2013 | 148 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2013 | 132 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2013 | 366 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1486 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2013 | 192 | 0.020 |
Why?
| | Vesicular Acetylcholine Transport Proteins | 1 | 2011 | 4 | 0.020 |
Why?
| | Phenyl Ethers | 1 | 2011 | 5 | 0.020 |
Why?
| | Vasoactive Intestinal Peptide | 1 | 2011 | 20 | 0.020 |
Why?
| | Wilms Tumor | 1 | 2013 | 85 | 0.020 |
Why?
| | Collagen | 1 | 2014 | 456 | 0.020 |
Why?
| | S100 Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2013 | 510 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2013 | 248 | 0.020 |
Why?
| | Hemagglutinins | 1 | 2011 | 10 | 0.020 |
Why?
| | Hernia, Diaphragmatic | 1 | 2011 | 67 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2834 | 0.020 |
Why?
| | Isoantibodies | 1 | 2011 | 57 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3540 | 0.020 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 136 | 0.020 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 191 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2012 | 294 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2010 | 50 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1257 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2182 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2014 | 553 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2117 | 0.020 |
Why?
| | HLA Antigens | 1 | 2011 | 225 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1833 | 0.020 |
Why?
| | Shock, Septic | 1 | 2012 | 216 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 264 | 0.020 |
Why?
| | Radiosurgery | 1 | 2013 | 400 | 0.020 |
Why?
| | Arthralgia | 1 | 2010 | 61 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2003 | 2637 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 976 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1886 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2155 | 0.020 |
Why?
| | Monocytes | 1 | 2012 | 538 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 1125 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2930 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5992 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 688 | 0.020 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2015 | 691 | 0.020 |
Why?
| | Endocrine System Diseases | 1 | 2007 | 35 | 0.020 |
Why?
| | Growth Disorders | 1 | 2007 | 86 | 0.020 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 118 | 0.020 |
Why?
| | Pulmonary Surfactants | 1 | 2007 | 102 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 2061 | 0.010 |
Why?
| | Prospective Studies | 1 | 2018 | 7990 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2007 | 255 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2608 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 2007 | 284 | 0.010 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 865 | 0.010 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2002 | 15 | 0.010 |
Why?
| | Purpura | 1 | 2002 | 18 | 0.010 |
Why?
| | Karyotyping | 1 | 2002 | 106 | 0.010 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2002 | 85 | 0.010 |
Why?
| | Hyperplasia | 1 | 2002 | 174 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2002 | 163 | 0.010 |
Why?
| | Bone Marrow | 1 | 2002 | 304 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2002 | 205 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2002 | 1054 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1173 | 0.010 |
Why?
| | RNA, Viral | 1 | 2002 | 688 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3863 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2002 | 2919 | 0.000 |
Why?
|
|
Galambos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|